MAIA Biotechnology, Inc. (MAIA)

3.4800 +0.0400 (+1.16%) As of 11:54AM EDT. Market open.

MAIA Biotechnology, Inc.

444 West Lake Street
Suite 1700
Chicago, IL 60606
United States
312 416 8592
https://maiabiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 13

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Vlad Vitoc M.B.A., M.D.	Co-Founder, President, CEO & Chairman of the Board of Directors	529.82k	N/A	1970
Mr. Jeffrey C. Himmelreich	Head of Finance	213.17k	N/A	1975
Dr. Sergei M. Gryaznov Ph.D.	Chief Scientific Officer	417.33k	N/A	1960
Linda Moreira	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Corporate governance

MAIA Biotechnology, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.